Soren Erik Bjorn

Title: Soren Erik Bjorn: Innovator in Pharmaceutical Composition

Introduction

Soren Erik Bjorn is a notable inventor based in Lyngby, Denmark. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative compositions that enhance therapeutic efficacy. With a total of 3 patents, his work has had a meaningful impact on medical science.

Latest Patents

Bjorn's latest patents include groundbreaking inventions. One of his notable patents is for "Derivatives of GLP-1 analogs," which relates to a pharmaceutical composition comprising a GLP-1 derivative having a lipophilic substituent and a surfactant. Another significant patent is "Pegylated factor VII glycoforms," which concerns a preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides. This invention highlights the incorporation of asparagine-linked and/or serine-linked oligosaccharide chains, with at least one oligosaccharide group covalently attached to a polymeric group.

Career Highlights

Throughout his career, Soren Erik Bjorn has worked with prominent companies in the pharmaceutical industry. He has been associated with Novo Nordisk A/S and Novo Nordisk Healthcare AG, where he has contributed to various innovative projects and research initiatives.

Collaborations

Bjorn has collaborated with esteemed colleagues, including Liselotte Bjerre Knudsen and Per Olaf Huusfeldt. These partnerships have fostered a collaborative environment that encourages innovation and the advancement of pharmaceutical research.

Conclusion

Soren Erik Bjorn's contributions to pharmaceutical innovations through his patents and collaborations underscore his role as a significant inventor in the field. His work continues to influence the development of effective medical treatments.